



**P Baas**

**Contact**

P Baas

## Publications (4)

Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel members. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. *Ann Oncol* 2011; 22:1507-1519.

Jörger M, Beijnen J, Huitema A, Rosing H, Vainchtein L, Jansen R, Smits P, Doodeman V, Baas P, Burgers J, Schellens J. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. *Cancer Chemother Pharmacol* 2011; 69:25-33.

Jörger M, deJong D, Burylo A, Burgers J, Baas P, Huitema A, Beijnen J, Schellens J. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non-small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. *Lung Cancer* 2011; 74:310-7.

Jörger M, Huitema A, van den Bongard H, Baas P, Schornagel J, Schellens J, Beijnen J. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. *British journal of clinical pharmacology* 2006; 62:71-80.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)